招商国证生物医药指数(LOF)C(012417)财务指标
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 本期已实现收益 |
-40,769,799.57 |
-318,724,037.27 |
-188,667,534.98 |
-319,646,675.74 |
| 本期利润 |
-93,790,680.68 |
115,242,928.68 |
38,989,900.23 |
-514,120,339.14 |
| 加权平均基金份额本期利润 |
-0.02 |
0.03 |
0.01 |
-0.11 |
| 本期加权平均净值利润率(%) |
-6.35 |
6.89 |
2.14 |
-27.49 |
| 本期基金份额净值增长率(%) |
-6.78 |
5.35 |
1.85 |
-22.96 |
| 期末可供分配利润 |
-2,652,561,676.82 |
-2,214,667,224.34 |
-2,696,922,526.17 |
-3,296,475,165.29 |
| 期末可供分配基金份额利润 |
-0.63 |
-0.61 |
-0.62 |
-0.63 |
| 期末基金资产净值 |
1,538,803,739.00 |
1,438,786,874.97 |
1,657,845,015.51 |
1,968,160,494.02 |
| 期末基金份额净值 |
0.37 |
0.39 |
0.38 |
0.37 |
| 基金份额累计净值增长率(%) |
-66.97 |
-64.57 |
-65.75 |
-66.37 |
微信公众号
证券之星APP
基本资料
